Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation

Joselle Cook; Kishore Rajendran; Andrea Ferrero; Preet Dhillon; Shaji Kumar; Francis Baffour

doi:10.1159/000531461

Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation

Joselle Cook, Kishore Rajendran, Andrea Ferrero, Preet Dhillon, Shaji Kumar, Francis Baffour

Research output: Contribution to journal › Article › peer-review

Abstract

Photon counting detector (PCD) computed tomography (CT) is a paradigm-shifting innovation in CT imaging which was recently granted approval for clinical use by the US Food and Drug Administration. PCD-CT allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma is important for the diagnosis and management of patients, the advent of PCD-CT heralds a new era in superior diagnostic evaluation of myeloma bone disease. In a first-in-human pilot study, patients with multiple myeloma were imaged with UHR-PCD-CT to validate and establish the utility of this technology in routine imaging and clinical care. We describe 2 cases from that cohort to highlight the superior imaging performance and diagnostic potential of PCD-CT for multiple myeloma compared to clinical standard EID-CT. We also discuss how the advanced imaging capabilities from PCD-CT enhances clinical diagnostics to improve care and overall outcomes for patients.

Original language	English (US)
Pages (from-to)	419-423
Number of pages	5
Journal	Acta Haematologica
Volume	146
Issue number	5
DOIs	https://doi.org/10.1159/000531461
State	Published - Jun 20 2023

Keywords

Bone disease
High-resolution imaging
Lytic lesion
Multiple myeloma
Photon counting computed tomography

ASJC Scopus subject areas

Hematology

Access to Document

10.1159/000531461

Cite this

@article{e9b4515a8cbf414db33862c114bd984e,

title = "Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation",

abstract = "Photon counting detector (PCD) computed tomography (CT) is a paradigm-shifting innovation in CT imaging which was recently granted approval for clinical use by the US Food and Drug Administration. PCD-CT allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma is important for the diagnosis and management of patients, the advent of PCD-CT heralds a new era in superior diagnostic evaluation of myeloma bone disease. In a first-in-human pilot study, patients with multiple myeloma were imaged with UHR-PCD-CT to validate and establish the utility of this technology in routine imaging and clinical care. We describe 2 cases from that cohort to highlight the superior imaging performance and diagnostic potential of PCD-CT for multiple myeloma compared to clinical standard EID-CT. We also discuss how the advanced imaging capabilities from PCD-CT enhances clinical diagnostics to improve care and overall outcomes for patients.",

keywords = "Bone disease, High-resolution imaging, Lytic lesion, Multiple myeloma, Photon counting computed tomography",

author = "Joselle Cook and Kishore Rajendran and Andrea Ferrero and Preet Dhillon and Shaji Kumar and Francis Baffour",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.",

year = "2023",

month = jun,

day = "20",

doi = "10.1159/000531461",

language = "English (US)",

volume = "146",

pages = "419--423",

journal = "Acta Haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "5",

}

TY - JOUR

T1 - Photon Counting Detector Computed Tomography

T2 - A New Frontier of Myeloma Bone Disease Evaluation

AU - Cook, Joselle

AU - Rajendran, Kishore

AU - Ferrero, Andrea

AU - Dhillon, Preet

AU - Kumar, Shaji

AU - Baffour, Francis

N1 - Publisher Copyright: © 2023 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.

PY - 2023/6/20

Y1 - 2023/6/20

N2 - Photon counting detector (PCD) computed tomography (CT) is a paradigm-shifting innovation in CT imaging which was recently granted approval for clinical use by the US Food and Drug Administration. PCD-CT allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma is important for the diagnosis and management of patients, the advent of PCD-CT heralds a new era in superior diagnostic evaluation of myeloma bone disease. In a first-in-human pilot study, patients with multiple myeloma were imaged with UHR-PCD-CT to validate and establish the utility of this technology in routine imaging and clinical care. We describe 2 cases from that cohort to highlight the superior imaging performance and diagnostic potential of PCD-CT for multiple myeloma compared to clinical standard EID-CT. We also discuss how the advanced imaging capabilities from PCD-CT enhances clinical diagnostics to improve care and overall outcomes for patients.

AB - Photon counting detector (PCD) computed tomography (CT) is a paradigm-shifting innovation in CT imaging which was recently granted approval for clinical use by the US Food and Drug Administration. PCD-CT allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma is important for the diagnosis and management of patients, the advent of PCD-CT heralds a new era in superior diagnostic evaluation of myeloma bone disease. In a first-in-human pilot study, patients with multiple myeloma were imaged with UHR-PCD-CT to validate and establish the utility of this technology in routine imaging and clinical care. We describe 2 cases from that cohort to highlight the superior imaging performance and diagnostic potential of PCD-CT for multiple myeloma compared to clinical standard EID-CT. We also discuss how the advanced imaging capabilities from PCD-CT enhances clinical diagnostics to improve care and overall outcomes for patients.

KW - Bone disease

KW - High-resolution imaging

KW - Lytic lesion

KW - Multiple myeloma

KW - Photon counting computed tomography

UR - http://www.scopus.com/inward/record.url?scp=85173570408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85173570408&partnerID=8YFLogxK

U2 - 10.1159/000531461

DO - 10.1159/000531461

M3 - Article

C2 - 37339614

AN - SCOPUS:85173570408

SN - 0001-5792

VL - 146

SP - 419

EP - 423

JO - Acta Haematologica

JF - Acta Haematologica

IS - 5

ER -

Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this